You searched for "AdvancedSolidTumors" from the Body Image.

Stage	Phase	Principal Investigator	Study prefix	Study number	Title (click hyperlink for more information)
	I	Adekunle Odunsi, MD PhD	PH	144908	(MDX1105-01) Phase I, Open-Label, Multicenter, Dose-Escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors
	I	Michael Wong, MD PhD FRCPC	I	126408	An Open Label Phase I Dose Finding Study Of TRC105 In Patients With Advanced Or Metastatic Solid Cancer For Whom Curative Therapy Is Unavailable
	I	Alex Adjei, MD PhD	I	150009	A Phase I Dose Escalation Study of ARQ197 Administered in Combination with Sorafenib in Adult Patients with Advanced Solid Tumors
	I	Grace Dy, MD	PH	99007	(CA187004) A Phase I Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-690514 in Combination with Paclitaxel and Carboplatin for Patients with Advanced or Metastatic Solid Tumors
	I	Marwan Fakih, MD	I	55305	A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) in Combination with 5-Fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) in Patients with Colorectal Cancer and other Solid Tumors(NCI#6789)
Advanced Malignancies	I	Renuka Iyer, MD	I	23204	An Open-Label, Dose Escalation study of Paricalcitol (Zemplar TM) {19-NOR-1 ALPHA, 25-(OH)2 D2] in Combination with Gemcitabine (Gemzar) [2',2' Diflurodeoxycytidine] in patients with advanced Malignancies
	I	Wen Wee Ma, MD	PH	135008	(A7471004) Phase I Targeted Combination Trial of PF-00299804 and CP-751,871 in Patients with Advanced Solid Tumors
	I	Alex Adjei, MD PhD	PH	119407	A Multi-Center Phase 1, Dose-Escalation Trial to Determine the Safety and Pharmacokinetics/Pharmacodynamics of RDEA119, a MEK Inhibitor, in Advanced Cancer Patients
	I	Wen Wee Ma, MD	I	137508	Phase I Dose Escalation Study of Gemcitabine and ON 01910.Na in Patients with Advanced or Metastatic Solid Tumors
Advanced	I	Roberto Pili, MD	I	150609	( C11981/1047/ON/US) An Open-Label Study to Determine the Maximum Tolerated Oral Dose of the Kinase Inhibitor CEP-11981 in Patients with Advanced Cancer
	I	Wen Wee Ma, MD	I	154309	(XL518-001) A Phase I Dose-Escalation of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects with Solid Tumors
	I	Alex Adjei, MD PhD	I	149609	(VEG105430) An Open-Label, Phase 1b Study to Assess the Long-Term Safety Profile of Pazopanib in Cancer Patients
	Ib	Grace Dy, MD	I	157909	(SHH4610g) A Phase 1b, Open-Label, Dose-Scheduling Study of HedgehogPathway Inhibitor GDC-0449 in Patients with Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Total number of Clinical Trials found: 13

Return to Search page